Mounjaro (Tirzepatide) Injection Guide

Mounjaro gained FDA approval on May 13, 2022, and is marketed by Eli Lilly and Company, which is based in the USA. Mounjaro activates both GLP-1 and GIP receptors, while other weight loss medications like Ozempic and Wegovy only target GLP-1 receptors.

Introduction to Mounjaro

Mounjaro, also known by its generic name tirzepatide, is a once weekly injection designed to help manage type 2 diabetes in adults and children aged 10 years and older. This innovative medication works by activating two key gut hormone receptors—GIP and GLP-1—which play a crucial role in regulating blood sugar levels and insulin production. By targeting both pathways, Mounjaro helps lower blood sugar levels, improve blood sugar control, and support healthy insulin production.

In addition to its benefits for blood sugar, Mounjaro has been shown to promote weight loss, especially when used alongside diet and exercise. Many patients experience improved blood sugar and significant weight loss as part of a comprehensive treatment plan that includes lifestyle changes and regular monitoring.

How Does Mounjaro Work?

Tirzepatide is a synthetic peptide that simultaneously activates two incretin hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-agonist approach, sometimes called “twincretin” therapy, produces greater metabolic effects than activating either receptor alone.

GLP-1 Receptor Activation

The GLP-1 component suppresses appetite through hypothalamic and brainstem receptor activation, slows gastric emptying to increase satiety, and enhances glucose-dependent insulin production from pancreatic beta cells. These effects are shared with all GLP-1 receptor agonists (semaglutide, liraglutide) but tirzepatide’s GLP-1 potency is approximately 5-fold lower than native GLP-1, balanced by the additive effects of GIP co-agonism.

GIP Receptor Activation

The GIP component is what distinguishes tirzepatide from pure GLP-1 receptor agonists. GIP receptor agonism enhances insulin production and secretion, improves beta cell function, and—crucially—appears to potentiate the weight loss effect of GLP-1 through mechanisms that are still being characterised. Preclinical data suggests GIP receptor activation in the central nervous system contributes to appetite suppression, while peripheral GIP signalling may improve adipose tissue metabolism and lipid handling. For a comparison of how tirzepatide’s mechanism differs from triple-agonist compounds, see our GIP/GLP-1/glucagon pathway analysis.

Net Metabolic Effects

The combined activation produces several coordinated metabolic improvements beyond weight loss: reduced fasting insulin and improved insulin sensitivity (HOMA-IR improved by 65–72% in SURMOUNT-1), reduced triglycerides (up to 36% reduction), increased HDL cholesterol, reduced liver fat content (up to 51% reduction), lowered systolic blood pressure (6–9 mmHg), and improved inflammatory markers (C-reactive protein reduction up to 48%).

How Does Mounjaro Work to Improve Blood Sugar?

Tirzepatide helps improve blood sugar through multiple mechanisms. It enhances glucose-dependent insulin production from pancreatic beta cells, meaning insulin secretion increases only when blood sugar glucose levels are elevated. This glucose-dependent action reduces the risk of hypoglycemia compared to older diabetes treatments. Additionally, tirzepatide suppresses glucagon secretion (which normally raises blood sugar glucose), slows the rate at which food enters the small intestine, and improves peripheral insulin sensitivity.

In SURPASS programme trials, the Mounjaro injection improved blood sugar control as measured by HbA1c by up to 2.58%, with many patients achieving target glycaemic levels.

Clinical Trial Weight Loss Data

The Mounjaro injection has been evaluated across two major clinical trial programmes: SURPASS (type 2 diabetes) and SURMOUNT (obesity/overweight). Together, these programmes enrolled over 25,000 participants and established tirzepatide as the most effective approved weight loss medication, demonstrating significant weight loss across all doses. However, it is important to note that Mounjaro is not approved for weight loss, but it has shown significant weight loss effects in clinical trials and is frequently prescribed off-label for this purpose.

*SURMOUNT-3 combined tirzepatide with intensive lifestyle intervention (1,200–1,500 kcal/day diet plus 150 min/week exercise), producing the highest weight loss ever recorded in a Phase 3 obesity trial with an approved medication. When compared to other weight loss medications such as Ozempic and Wegovy, Mounjaro has demonstrated superior efficacy in clinical trials.

Key Efficacy Findings

• Dose-response relationship: Weight loss scales clearly with dose. The 15 mg dose consistently outperforms 10 mg and 5 mg across all trials
• ≥5% weight loss: Achieved by 89–91% of participants on 15 mg (SURMOUNT-1) vs 35% on placebo
• ≥20% weight loss: Achieved by 56.7% on 15 mg, 47.5% on 10 mg, and 32.1% on 5 mg (SURMOUNT-1)
• ≥25% weight loss: Achieved by 36.2% on 15 mg (SURMOUNT-1)—more than one-third of patients lost a quarter of their body weight
• Weight loss plateau: Maximum weight loss typically occurs at 60–72 weeks. Weight stabilises rather than continuing to decline indefinitely

Head-to-Head vs Semaglutide

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes (n=1,879). Tirzepatide 15 mg produced 13.1% weight loss vs 6.7% with semaglutide 1 mg—a nearly 2-fold difference. HbA1c reduction was also superior: −2.58% with tirzepatide 15 mg vs −1.86% with semaglutide 1 mg. While this comparison used the diabetes dose of semaglutide (not the higher Wegovy 2.4 mg dose), the margin of superiority was substantial. For a visual summary of what these trial numbers translate to in practice, see our Mounjaro before and after weight loss results. For a broader comparison including next-generation compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.

Complete Dosing Schedule

The Mounjaro injection is administered as a once weekly injection using a pre-filled pen. Tirzepatide uses a gradual dose escalation strategy to minimise gastrointestinal side effects. The starting dose is intentionally subtherapeutic for weight loss, functioning primarily as a tolerability assessment. Your healthcare provider determines the appropriate dose and escalation pace based on individual tolerability and treatment goals. Your healthcare provider will monitor your current dose and adjust it as needed for effectiveness and safety.

It is important to note the timing of your last dose and plan for your next dose to maintain consistent therapy and optimal results.

Always read the Instructions for Use and Medication Guide that come with your Mounjaro pen before using it. You should change (rotate) injection sites with each injection of Mounjaro. Dispose of your used Mounjaro pen in a sharps disposal container and do not throw it in the household trash.

Injection Administration

• Injection sites: Abdomen (including the upper stomach), front of thigh, or upper arm. You can inject in the same area (such as the abdomen or upper arm) but should choose a different spot within that area for each injection. Rotate injection sites with each injection to reduce local reactions and ensure proper absorption
• Timing: Inject on the same day each week, any time of day, with or without food. If a dose is missed, take it as soon as you remember within 4 days after the missed dose; if more than 4 days have passed, skip and resume the next scheduled dose
• Storage: Refrigerate unused pens at 2–8°C. May store at room temperature (up to 30°C) for up to 21 days. Do not freeze
• Pen format: Available as a pre-filled single-dose pen with a hidden needle. Each pen delivers one fixed dose. No reconstitution or dose measurement required
• Do not mix insulin: Do not mix insulin or other injectable medications in the same syringe or pen as tirzepatide. Mounjaro and insulin can be injected in the same area but not in the same injection—administer each injection separately at different spots

How to Store Mounjaro Pens

Store Mounjaro pens in the refrigerator at 2–8°C (36–46°F) until ready to use. Each pre-filled pen can be stored at room temperature (up to 30°C / 86°F) for a maximum of 21 days. Do not freeze Mounjaro, and do not use a pen that has been frozen. Store Mounjaro away from direct heat and light. Each pen is for single use only—discard after administration even if medication remains. Check the expiration date before each use and contact your healthcare provider if you have questions about storage or handling.

For detailed guidance on research compound dosing protocols, see our retatrutide dosage guide, which includes dose escalation principles applicable to incretin-class research. For broader information on peptide storage requirements, see our peptide stability and storage guide.

Mounjaro Prescription Criteria

To qualify for a Mounjaro prescription, patients typically need a personal or family history of type 2 diabetes and ongoing challenges with controlling their blood sugar levels. Healthcare providers will carefully review each patient’s medical background, current blood sugar levels, and any history of related health issues before recommending Mounjaro.

It is important to note that Mounjaro should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as these conditions increase the risk of serious complications. Patients who have experienced severe abdominal pain, have kidney problems, or have had allergic reactions to similar medications should discuss these concerns with their healthcare provider before starting treatment. Open communication with healthcare providers ensures that Mounjaro is used safely and effectively as part of a personalized diabetes management plan.

Mounjaro Injection Side Effects and Safety Profile

The Mounjaro injection side effect profile is dominated by gastrointestinal adverse events, consistent with its mechanism of action. Most side effects of Mounjaro are mild to moderate and decrease over time as the body adjusts. These effects are most common during dose escalation and generally attenuate with continued treatment. Healthcare providers advise patients to report persistent symptoms early.

In addition to gastrointestinal side effects, users of Mounjaro often experience lower blood pressure, improved cholesterol levels, and better blood sugar regulation alongside weight loss.

It is important to note that severe pain in the abdomen or back may be a warning sign of pancreatitis and should prompt immediate medical attention.

Common Side Effects (SURMOUNT-1, 15 mg)

• Nausea: 33.3% (vs 6.7% placebo). Most episodes were mild and peaked during first 4–8 weeks of each dose increase
• Diarrhea: 23.0% (vs 7.3% placebo). Typically self-limiting within 1–2 weeks
• Vomiting: 12.8% (vs 2.5% placebo). More common during initial dose escalation
• Constipation: 17.1% (vs 4.8% placebo). May require dietary fibre supplementation
• Injection site reactions: 7.2% (vs 2.0% placebo). Redness, itching, or pain at injection site
• Decreased appetite: 16.0% (considered a therapeutic effect rather than adverse event by some researchers)

Common Side Effects Management

While taking Mounjaro, some patients may experience common side effects such as nausea, diarrhea, decreased appetite, vomiting, or mild abdominal pain. To help manage these side effects of Mounjaro, it’s recommended to take the injection with food, drink plenty of fluids, and gradually increase the dose as directed by your healthcare provider. If you notice persistent or bothersome symptoms, such as severe stomach problems, trouble swallowing, or trouble breathing, contact your healthcare provider immediately. Reporting any unusual or severe side effects ensures that your treatment plan can be adjusted for your safety and comfort. Most common side effects tend to improve over time as your body adjusts to the medication.

Hair Loss

Hair loss (alopecia) has been reported by some patients during Mounjaro injection treatment, though it was not a commonly reported side effect in the SURMOUNT clinical trials. Hair loss associated with rapid and significant weight loss is a well-documented phenomenon called telogen effluvium, where the stress of caloric deficit and weight change triggers a temporary shift in the hair growth cycle. This type of hair loss is generally reversible once weight stabilises. Healthcare providers may recommend biotin supplementation, adequate protein intake, and monitoring of iron and thyroid function in patients experiencing hair loss during treatment.

Serious Adverse Events

Serious adverse events occurred in 6.9% of tirzepatide 15 mg patients vs 5.8% on placebo in SURMOUNT-1. Rare but serious conditions related to Mounjaro injection include pancreatitis, gallbladder problems, kidney injury, severe allergic reactions, hypoglycemia, and a risk of thyroid cancer. Specific serious risks include:

• Pancreatitis: Reported in 0.1–0.2% of patients. Discontinue if suspected. All GLP-1 class medications carry this risk
• Gallbladder disease: Cholelithiasis and cholecystitis rates increase with rapid weight loss. Incidence was 1.5% with tirzepatide 15 mg vs 0.4% placebo
• Thyroid cancer (C-cell tumours): Boxed warning based on rodent studies showing thyroid medullary carcinoma with GLP-1 receptor agonists. Not confirmed in humans. Contraindicated in patients with personal or family history of medullary thyroid cancer or MEN 2 syndrome
• Hypoglycemia: Low risk as monotherapy (tirzepatide has glucose-dependent insulin secretion). Risk increases when combined with insulin or sulfonylureas

For a comprehensive side effect comparison across the GLP-1 drug class, see our Ozempic vs Mounjaro vs Wegovy side effects analysis and retatrutide safety profile.

Low Blood Sugar Risk

Mounjaro can increase the risk of low blood sugar, especially when used in combination with other diabetes medications or insulin. Symptoms of low blood sugar include shakiness, dizziness, sweating, confusion, and irritability. To prevent and manage low blood sugar, keep a quick source of sugar—such as glucose tablets or hard candy—readily available. It’s important to inform your healthcare providers and family members about the signs of low blood sugar and how to respond if it occurs. Regular monitoring of your blood sugar and open communication with your healthcare team can help minimize risks and keep your treatment on track.

Deep Sedation Warning

If you are scheduled for surgery or any procedure that involves anesthesia or deep sedation, let your healthcare providers know that you are taking Mounjaro. This medication may increase the risk of food or liquid entering the lungs during such procedures. Your healthcare provider may need to adjust your treatment plan or take special precautions to ensure your safety. Always follow your healthcare provider’s instructions before and after any surgical procedure to reduce the risk of complications and support a smooth recovery.

Important Safety Information for the Mounjaro Injection

Before starting the Mounjaro injection, patients should discuss their complete medical history with their healthcare provider. If you experience severe side effects or emergencies, such as signs of anaphylaxis, seek medical help immediately. It is also important to work with your healthcare professional to develop individualized treatment plans tailored to your specific needs. The following safety considerations apply to all patients using tirzepatide, whether prescribed as Mounjaro for type 2 diabetes or Zepbound for obesity management.

Who Should Not Use the Mounjaro Injection

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This contraindication is based on a boxed warning from rodent studies showing thyroid C-cell tumours with GLP-1 receptor agonists. Healthcare providers should obtain a thorough family history before prescribing. Patients with a personal or family history of pancreatitis should also be closely monitored. Tirzepatide should not be used in patients with known hypersensitivity to the drug or any of its excipients.

Pregnancy, Breastfeeding, and the Unborn Baby

Tirzepatide may cause harm to an unborn baby based on animal reproduction studies. Patients who are pregnant or planning to become pregnant should not use Mounjaro. Healthcare providers recommend discontinuing tirzepatide at least 2 months before a planned pregnancy due to its long half-life. It is not known whether tirzepatide passes into breast milk or whether it could affect breast milk production. Because of the potential risk to an unborn baby or nursing infant, patients should consult their healthcare provider about the risks and benefits of using tirzepatide during breastfeeding. Women of childbearing potential should use effective contraception while receiving treatment.

Mounjaro and Birth Control

Mounjaro can affect how oral contraceptives are absorbed. Because tirzepatide slows gastric emptying, it may reduce the effectiveness of birth control pills and other oral contraceptives. Healthcare providers recommend that patients taking oral contraceptives switch to a non-oral form of birth control (such as an IUD, implant, or injection) or use a backup barrier method for 4 weeks after initiating treatment and for 4 weeks after each dose increase.

This interaction between the Mounjaro injection and oral contraceptives is particularly important during dose escalation when the effects on gastric motility are most pronounced. Patients should discuss birth control options with their healthcare provider before starting treatment.

Kidney Problems and Dehydration

Mounjaro can cause dehydration due to gastrointestinal side effects such as nausea, vomiting, and diarrhea. Severe dehydration may lead to kidney problems, including acute kidney injury and worsening of chronic kidney disease. Patients should be advised to maintain adequate hydration, particularly during dose escalation. It is important to drink fluids regularly to help prevent dehydration and reduce the risk of kidney problems, especially during periods of gastrointestinal symptoms.

Signs of dehydration include dark yellow urine, reduced urine output, dizziness, and dry mouth. Healthcare providers should monitor kidney function in patients with pre-existing kidney problems and in those experiencing persistent gastrointestinal symptoms.

Diabetic Retinopathy

Rapid improvement in blood sugar glucose levels can temporarily worsen diabetic retinopathy in patients with a history of the condition. In the SURPASS clinical trial programme, complications of diabetic retinopathy were reported in some patients treated with tirzepatide. Patients with a history of diabetic retinopathy should be monitored by their healthcare provider and should have regular eye examinations during treatment. The risk of diabetic retinopathy complications appears to be related to the speed and magnitude of glycaemic improvement rather than a direct drug effect.

Gastroparesis and Problems Digesting Food

Because tirzepatide slows gastric emptying, it can worsen pre-existing problems digesting food, including gastroparesis. Patients who experience severe or persistent trouble swallowing, abdominal bloating, or problems digesting food should contact their healthcare provider. In rare cases, trouble swallowing may indicate a more serious condition requiring immediate evaluation. Healthcare providers should exercise caution when prescribing Mounjaro to patients with a history of gastroparesis or severe gastrointestinal motility disorders.

Allergic Reactions

Serious allergic reactions have been reported with the Mounjaro injection, though they are rare. Symptoms of a serious allergic reaction include swelling of the face, lips, tongue, or throat, severe rash or itching, trouble swallowing or breathing, rapid heartbeat, and feeling faint. Patients who experience signs of a serious allergic reaction should seek immediate medical attention and discontinue tirzepatide. Injection site reactions (redness, itching, or swelling) are more common and generally mild, affecting 3–7% of patients.

When to Seek Immediate Medical Attention

Patients using Mounjaro should seek immediate medical attention if they experience: severe abdominal pain that does not go away (possible pancreatitis), symptoms of a serious allergic reaction (difficulty breathing, swelling of face or throat), signs of severe dehydration (dark yellow urine, minimal urine output, dizziness), vision changes in patients with diabetic retinopathy, or severe hypoglycemia when used with insulin or sulfonylureas. Healthcare providers should ensure patients understand these warning signs before starting treatment.

Body Composition and Muscle Preservation

One of the key clinical questions with any significant weight loss intervention is the ratio of fat mass to lean mass lost. Excessive lean mass (muscle) loss can impair functional capacity, reduce basal metabolic rate, and increase frailty risk, particularly in older adults. Healthcare providers increasingly monitor body composition alongside scale weight when prescribing the Mounjaro injection.

SURMOUNT-1 body composition substudy data (DXA analysis in a subset of participants) showed that approximately 75–82% of total weight lost with tirzepatide 15 mg was fat mass, with 18–25% being lean mass. This fat-to-lean ratio compares favourably to semaglutide (STEP 1 reported approximately 61% fat, 39% lean mass loss) and is closer to the optimal ratio seen with surgical interventions.

The GIP receptor component may contribute to this more favourable body composition outcome. Preclinical studies suggest GIP signalling in adipose tissue promotes lipid storage efficiency and may preferentially direct energy metabolism toward fat oxidation over muscle catabolism, though the precise mechanisms in humans remain under investigation. For a detailed analysis of lean mass preservation across weight loss drugs, see our GLP-1 muscle loss and body composition review.

Cardiovascular and Metabolic Benefits

Beyond significant weight loss, the Mounjaro injection produces meaningful improvements in cardiometabolic risk factors. Healthcare providers monitoring patients on tirzepatide have documented consistent benefits across multiple parameters in the SURPASS and SURMOUNT programmes:

• Blood pressure: Systolic BP reduction of 6–9 mmHg, comparable to a single antihypertensive medication
• Lipids: Triglyceride reduction of 19–36%, LDL cholesterol reduction of 5–10%, HDL cholesterol increase of 5–8%
• Liver fat: Hepatic fat content reduced by up to 51% in a SURPASS-3 MRI substudy, making tirzepatide a potential treatment for metabolic-associated steatotic liver disease (MASLD)
• Inflammatory markers: C-reactive protein (CRP) reduced by 38–48%, reflecting reduced systemic inflammation
• Waist circumference: Average reduction of 14.5 cm at the 15 mg dose in SURMOUNT-1

The SURPASS-CVOT (cardiovascular outcomes trial) is evaluating tirzepatide’s impact on major adverse cardiovascular events (MACE) in high-risk patients. While results are pending, semaglutide’s SELECT trial demonstrated a 20% MACE reduction, establishing a cardiovascular benefit for the GLP-1 receptor agonist class. Beyond metabolic applications, tirzepatide (as Zepbound) received FDA approval for obstructive sleep apnea in December 2024.

How Does the Mounjaro Injection Compare?

The Mounjaro injection occupies a specific position in the obesity pharmacotherapy landscape: more effective than all approved single-agent prescription medicines, but potentially exceeded by next-generation compounds in development. Mounjaro is a once-weekly injection that can be self-administered and should be used alongside dietary changes and exercise. Most agents listed below are administered as a once weekly injection (except oral formulations of semaglutide). Healthcare providers consider efficacy, tolerability, availability, and cost when choosing between these options.

For detailed comparisons, see our weight loss injections comparison guide, CagriSema vs tirzepatide analysis, and survodutide profile.

The Mounjaro Injection in Dubai & the UAE

Tirzepatide (Mounjaro) availability in the UAE is expanding but remains more limited than established options like Saxenda and Ozempic. Healthcare providers in the UAE have been prescribing this once weekly injection since its MoHAP registration. As of early 2026:

• Registration: Mounjaro has received MoHAP registration for type 2 diabetes. The obesity indication (Zepbound) is not yet separately registered in the UAE
• Availability: Available through select hospital pharmacies (Cleveland Clinic Abu Dhabi, Mediclinic, American Hospital Dubai) and specialist endocrinology or obesity management clinics. Not yet widely stocked in community pharmacies
• Prescription: Requires a valid prescription from a licensed endocrinologist, diabetologist, or obesity medicine specialist. Off-label prescribing for weight management is at the clinician’s discretion
• Cost: Approximately AED 1,500–2,500 per month depending on dose and pharmacy. Insurance coverage is typically limited to diabetes indications only
• Supply: Intermittent supply constraints mirror global patterns. Eli Lilly has invested over $18 billion in manufacturing capacity expansion to address global demand

For alternative treatments currently accessible in the UAE, see our Ozempic alternatives in Dubai guide and GLP-1 medications UAE availability and cost overview.

What Happens After Stopping the Mounjaro Injection?

SURMOUNT-4 directly addressed the discontinuation question. After a 36-week open-label tirzepatide run-in (during which participants lost an average of 20.9% body weight—significant weight loss by any measure), patients were randomised to continue tirzepatide or switch to placebo for 52 weeks. Those who switched to placebo regained approximately 14% of body weight, while those who continued tirzepatide lost an additional 5.5%.

This confirms that tirzepatide, like all GLP-1-based medications, treats the biological drivers of obesity without permanently correcting them. Discontinuation leads to weight regain as appetite-regulating mechanisms return to their pre-treatment state. Current consensus frames these medications as chronic treatments for a chronic disease, similar to statins for cholesterol or antihypertensives for blood pressure. Healthcare providers should discuss long-term treatment expectations with patients before starting the Mounjaro injection. For a detailed analysis, see our GLP-1 discontinuation and weight regain data review.